{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:38:19Z","timestamp":1784039899361,"version":"3.55.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jtha.2023.08.031","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T12:17:46Z","timestamp":1695212266000},"page":"3432-3449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacokinetic-guided versus standard prophylaxis in hemophilia: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"21","author":[{"given":"Daniel","family":"Kraemmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"K\u00f6nigsbr\u00fcgge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Moik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Wildner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cihan","family":"Ay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Pabinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2023.08.031_bib1","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1055\/s-0037-1615621","article-title":"Factor VIII and Factor IX Subcommittee. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis","volume":"85","author":"White","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.08.031_bib2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(15)01123-X","article-title":"The past and future of haemophilia: diagnosis, treatments, and its complications","volume":"388","author":"Peyvandi","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2023.08.031_bib3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.08.031_bib4","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1111\/jth.13811","article-title":"Effect of late prophylaxis in hemophilia on joint status: a randomized trial","volume":"15","author":"Manco-Johnson","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.08.031_bib5","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1538-7836.2011.04214.x","article-title":"A\u00a0randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)","volume":"9","author":"Gringeri","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.08.031_bib6","first-page":"CD014201","article-title":"Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B","volume":"8","author":"Olasupo","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jtha.2023.08.031_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH Guidelines for the Management of Hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.08.031_bib8","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1111\/hae.13215","article-title":"Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement","volume":"23","author":"Iorio","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.08.031_bib9","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1538-7836.2010.03767.x","article-title":"Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile","volume":"8","author":"Santagostino","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.08.031_bib10","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1365-2516.2011.02539.x","article-title":"Clinical severity of haemophilia A: does the classification of the 1950s still stand?","volume":"17","author":"den Uijl","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.08.031_bib11","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/hae.12592","article-title":"Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A","volume":"21","author":"Kepa","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.08.031_bib12","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00228-009-0676-x","article-title":"Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A","volume":"65","author":"Bj\u00f6rkman","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2023.08.031_bib13","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2516.2009.02191.x","article-title":"Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A","volume":"16","author":"Bj\u00f6rkman","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.08.031_bib14","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jth.13867","article-title":"Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH","volume":"15","author":"Iorio","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.08.031_bib15","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/rth2.12106","article-title":"Performing and interpreting individual pharmacokinetic profiles in patients with hemophilia A or B: rationale and general considerations","volume":"2","author":"Iorio","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.08.031_bib16","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jtha.2023.08.031_bib17","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jtha.2023.08.031_bib18","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.jtha.2023.08.031_bib19","series-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane","article-title":"Including non-randomized studies on intervention effects","author":"Reeves","year":"2022"},{"key":"10.1016\/j.jtha.2023.08.031_bib20","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jtha.2023.08.031_bib21","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jtha.2023.08.031_bib22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2516.2010.02383.x","article-title":"Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels","volume":"17","author":"Den Uijl","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.08.031_bib23","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3102\/10769986030003261","article-title":"Bias and efficiency of meta-analytic variance estimators in the random-effects model","volume":"30","author":"Viechtbauer","year":"2005","journal-title":"J\u00a0Educ Behav Stat"},{"key":"10.1016\/j.jtha.2023.08.031_bib24","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range","volume":"27","author":"Luo","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.jtha.2023.08.031_bib25","series-title":"A\u00a0language and environment for statistical computing. R Foundation for Statistical Computing [Internet]","year":"2022"},{"key":"10.1016\/j.jtha.2023.08.031_bib26","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jclinepi.2007.11.010","article-title":"Contour-enhanced meta-analysis funnel plots help distinguish publication bias\u00a0from other causes of asymmetry","volume":"61","author":"Peters","year":"2008","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jtha.2023.08.031_bib27","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1046\/j.1365-2516.1997.00091.x","article-title":"Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A","volume":"3","author":"Carlsson","year":"1997","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.08.031_bib28","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1538-7836.2011.04611.x","article-title":"A\u00a0randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management","volume":"10","author":"Valentino","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.08.031_bib29","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1182\/blood.2020005673","article-title":"Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study","volume":"137","author":"Klamroth","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.08.031_bib30","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1111\/hae.14635","article-title":"Individualised prophylaxis based on personalised target trough FVIII level optimised clinical outcomes in paediatric patients with severe haemophilia A","volume":"28","author":"Huang","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.08.031_bib31","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1111\/hae.14336","article-title":"Pharmacokinetic-guided prophylaxis improved clinical outcomes in paediatric patients with severe haemophilia A","volume":"27","author":"Huang","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.08.031_bib32","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood-2013-10-529974","article-title":"Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A","volume":"123","author":"Mahlangu","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.08.031_bib33","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/hae.13251","article-title":"PK-guided personalized prophylaxis with Nuwiq\u00ae (human-cl rhFVIII) in adults with severe haemophilia A","volume":"23","author":"Lissitchkov","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.08.031_bib34","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa1305074","article-title":"Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B","volume":"369","author":"Powell","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.08.031_bib35","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/hae.13953","article-title":"Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: final results from the ASPIRE extension study","volume":"26","author":"Nolan","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.08.031_bib36","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1111\/hae.14052","article-title":"Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A","volume":"26","author":"Chowdary","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.08.031_bib37","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1111\/hae.14036","article-title":"Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B-YOND extension study","volume":"26","author":"Pasi","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.08.031_bib38","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.thromres.2022.06.001","article-title":"Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII products","volume":"216","author":"Meg\u00edas-Vericat","year":"2022","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2023.08.031_bib39","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.thromres.2018.12.027","article-title":"Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A","volume":"174","author":"Meg\u00edas-Vericat","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2023.08.031_bib40","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.thromres.2021.07.009","article-title":"Clinical benefits of a Bayesian model for plasma-derived factor VIII\/VWF after one year of pharmacokinetic-guided prophylaxis in severe\/moderate hemophilia A patients","volume":"205","author":"Meg\u00edas-Vericat","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2023.08.031_bib41","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/MBC.0000000000000261","article-title":"Adult severe haemophilia A patients under long-term prophylaxis with factor VIII in routine clinical practice","volume":"26","author":"Mingot-Castellano","year":"2015","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jtha.2023.08.031_bib42","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1111\/hae.13540","article-title":"Improvement in clinical outcomes and replacement factor VIII use in patients with haemophilia A after factor VIII pharmacokinetic-guided prophylaxis based on Bayesian models with myPKFiT","volume":"24","author":"Mingot-Castellano","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.08.031_bib43","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.thromres.2018.11.017","article-title":"Clinical outcomes in hemophilia A patients undergoing tailoring of prophylaxis based on population-based pharmacokinetic dosing","volume":"173","author":"Nagao","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2023.08.031_bib44","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/hae.14700","article-title":"Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients","volume":"29","author":"Rakmanotham","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.08.031_bib45","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1055\/s-0039-1677700","article-title":"Impact of adopting population pharmacokinetics for tailoring prophylaxis in haemophilia a patients: a historically controlled observational study","volume":"119","author":"Stemberger","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.08.031_bib46","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000521360","article-title":"Efficacy of individualized preventive treatment of patients with severe hemophilia a guided by multiple clinical parameters and pharmacokinetics","volume":"145","author":"Wang","year":"2022","journal-title":"Acta Haematol"},{"key":"10.1016\/j.jtha.2023.08.031_bib47","doi-asserted-by":"crossref","first-page":"8904","DOI":"10.4081\/hr.2021.8904","article-title":"Impact of pharmacokinetics to reduce bleeding in a cohort of patients with severe hemophilia A in a personalized comprehensive management program","volume":"13","author":"Sarmiento Doncel","year":"2021","journal-title":"Hematol Rep"},{"key":"10.1016\/j.jtha.2023.08.031_bib48","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.thromres.2017.07.003","article-title":"PK-driven prophylaxis versus standard prophylaxis: when a tailored treatment may be a real and achievable cost-saving approach in children with severe hemophilia A","volume":"157","author":"Pasca","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2023.08.031_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2019.08.022","article-title":"Savings without changing: how to use the MyPKfit\u00ae device to improve treatment strategies in a cohort of patients with haemophilia A","volume":"183","author":"Pasca","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2023.08.031_bib50","first-page":"374","article-title":"Optimising prophylaxis outcomes and costs in haemophilia patients switching to recombinant FVIII-Fc: a single-centre real-world experience","volume":"18","author":"Tagliaferri","year":"2020","journal-title":"Blood Transfus"},{"key":"10.1016\/j.jtha.2023.08.031_bib51","first-page":"505","article-title":"The impact of pharmacokinetic-guided prophylaxis on clinical outcomes and\u00a0healthcare resource utilization in hemophilia A patients: real-world evidence from the CHESS II study","volume":"13","author":"Ferri Grazzi","year":"2022","journal-title":"J\u00a0Blood Med"},{"key":"10.1016\/j.jtha.2023.08.031_bib52","doi-asserted-by":"crossref","DOI":"10.1177\/1076029620950836","article-title":"Safety, Immunogenicity, and hemostatic efficacy of Nonacog Gamma in patients with severe or moderately severe hemophilia B: a continuation study","volume":"26","author":"Windyga","year":"2020","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.jtha.2023.08.031_bib53","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1365-2516.2012.02879.x","article-title":"Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy","volume":"18","author":"Lindvall","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.08.031_bib54","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1007\/s12325-022-02220-3","article-title":"Cost-effectiveness analysis of pharmacokinetic-guided prophylaxis versus standard prophylaxis in adults with severe hemophilia A in China","volume":"39","author":"Gu","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtha.2023.08.031_bib55","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s13643-015-0144-x","article-title":"Do alternative methods for analysing count data produce similar estimates? Implications for meta-analyses","volume":"4","author":"Herbison","year":"2015","journal-title":"Syst Rev"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623006621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623006621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:41:23Z","timestamp":1761536483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783623006621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":55,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1538783623006621"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2023.08.031","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic-guided versus standard prophylaxis in hemophilia: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2023.08.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}